LL-37 vs KPV

Side-by-side comparison of LL-37, KPV — mechanism, dosing, half-life, side effects, and research status.

← Pick different peptides
Attribute LL-37 LL-37 (Human Cathelicidin Antimicrobial Peptide) Recovery KPV KPV (Lys-Pro-Val) — Alpha-MSH Tripeptide Recovery
Basics
Molecular type Human CathelicidinAlpha-MSH C-terminal Tripeptide
Amino acids 373
Molecular weight 4,493.3 Da355.4 Da
Half-life Short (hours)Short (hours)
Route(s) Subcutaneous, Topical, IntranasalSubcutaneous, Oral (GI conditions), Topical
Mechanism & Research
Primary mechanism LL-37 disrupts microbial membranes through electrostatic interaction — its cationic amphipathic helical structure inserts into negatively charged bacterial membranes, causing lethal membrane permeabilisation. This mechan… KPV binds melanocortin receptors (MC1R and MC3R) expressed on immune cells, epithelial cells, and neurons. Receptor activation suppresses NF-κB-mediated pro-inflammatory cytokine production (TNF-α, IL-6, IL-8) and drives…
Research status Research Compound Research Compound
Evidence summary LL-37 has been studied extensively for wound healing, respiratory infections (including COVID-19 lung immunity), and more recently for senolytic applications. Its broad antimicrobial and immunomodulatory profile makes it… KPV has robust preclinical data for inflammatory bowel conditions (Crohn's disease, ulcerative colitis models) and wound healing. Oral nanoparticle formulations have been developed to improve colonic delivery.
Protocol & Dosing
Typical dose 1–5 mg per injection or topical application500 mcg–2 mg/day (SC); variable oral dosing
Frequency DailyOnce or twice daily
Duration 4–8 weeks4–8 weeks
Timing Any timeAny time; pre-meals for GI applications
Safety
Common side effects
  • Injection site pain (cytokine release)
  • Mild erythema
  • Headache (rare)
  • Injection site redness (SC)
  • Mild skin darkening (possible — MC1R activity)
  • Headache (rare)
Contraindications
  • Autoimmune conditions (immune stimulation)
  • Active lupus (LL-37 is a lupus autoantigen in some patients)
  • Pregnancy (no data)
  • Known melanocortin sensitivity
  • Pregnancy (insufficient data)
  • Active melanoma (MC1R concern)
Anti-doping Not Prohibited Not Prohibited
Deeper reading
Related peptides BPC-157, GHK-Cu, KPV BPC-157, LL-37, TB-500
Full profile Read full LL-37 profile → Read full KPV profile →

Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.